Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome
Indian Journal of Cancer · 2024
DOI: 10.4103/ijc.ijc_1283_20 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Muhammed M Atci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
We aimed to evaluate the data of perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy regimen in locally advanced gastric cancer (LAGC) patients with real-life experience.
Methods
In this retrospective study, LAGC patients who received perioperative FLOT chemotherapy regimen between 2017 and 2020 were included. The patients were grouped according to tumor regression grade (TRG): histopathological responders (complete/moderate response) and histopathological non-responders (minimal/poor response). The factors affecting TRG were evaluated and its relationship to clinical outcome was analyzed by disease-free survival (DFS) and overall survival (OS).
Results
A total of 141 LAGC patients were included. Median age of patients was 62 (range: 35–75) years of whom 69.5% were men. According to TRG, 41 (29.1%) patients were histopathological responders (College of American Pathologists (CAP)-TRG 0/1). Grade, perineural and lymphovascular invasion, clinical stage, tumor markers (Carcinoembryonic antigen (CEA) and Carbohydrate antigen (CA)19-9), radiological response, and ypTNM stage were statistically significant in univariate analysis and lymphovascular invasion was detected as an independent factor in multivariate analysis for TRG. Grade 3-4 toxicities were observed in only 28 (19.9%) patients. Two years DFS and OS rates were higher in the histopathological responder group (100% and 100%) compared to the histopathological non-responder group (59% and 52.9%) ( P = 0.01 and P = 0.02, respectively).
Conclusion
In our study, it was found that the FLOT regimen had a favorable TRG and a safe toxicity profile in gastric cancer patients. In addition, while lymphovascular invasion could predict TRG, the survival and disease recurrence were positively affected by the favorable TRG response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu City Hospital, Istanbul, Turkey.
ORCID-Profile: Muhammed M Atci, Saban Secmeler, Abdullah Sakin, Serdar Arici, Oguzhan Selvi, Ruhper Cekin, Nurgul Yasar, Caglayan Geredeli, Sener Cihan
Zitieren
APA
Atci, M. M., Secmeler, S., Sakin, A., Arici, S., Can, O., Selvi, O., Cekin, R., Yasar, N., Geredeli, C., & Cihan, S. (2024). Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1283_20
Vancouver
Atci MM, Secmeler S, Sakin A, Arici S, Can O, Selvi O, et al. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_1283_20
BibTeX
@article{Atci2024,
author = {Atci, Muhammed M and Secmeler, Saban and Sakin, Abdullah and Arici, Serdar and Can, Orcun and Selvi, Oguzhan and Cekin, Ruhper and Yasar, Nurgul and Geredeli, Caglayan and Cihan, Sener},
title = {Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome},
journal = {Indian Journal of Cancer},
year = {2024},
doi = {10.4103/ijc.ijc_1283_20}
}
EUVIMED